Side effects under investigation.
Conclusions: Treatment with rosuvastatin at a dose of 10 mg per day resulted in a significantly lower risk of cardiovascular events than placebo in an intermediate-risk, ethnically diverse population without cardiovascular disease. (Funded by the Canadian Institutes of Health Research and AstraZeneca; HOPE-3 ClinicalTrials.gov number, NCT00468923.)
Meldonium is also known as mildronate, it increases exercise capacity in athletes and the Olympic figure skater Ekaterina Bobrova admitted to testing positive to the drug on Monday
In a registry-based cohort study, Seena Fazel and colleagues test for within-individual associations between SSRI prescription and violent crime.
There are multiple links in the WP article to the original studies.
Thought I would add a link to the actual FDA alert.
via Safety Alerts for Human Medical Products > Non-aspirin Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Drug Safety Communication – FDA Strengthens Warning of Increased Chance of Heart Attack or Stroke.
NSAIDs can increase the risk of heart attack or stroke in patients with or without heart disease or risk factors for heart disease. A large number of studies support this finding, with varying estimates of how much the risk is increased, depending on the drugs and the doses studied.
There’s also the issue of cost. The medicines are expected to come with a price tag of $7,000 to $12,000 per patient per year, according to the Wall Street Journal’s Pharmalot blog, costing the US health system as much as $23 billion a year. “These injectable drugs are already viewed by payers as potential budget busters along the lines of treatments for hepatitis C and some cancers,” Ed Silverman wrote.